In bioassay research you will find analysis of total androgenic or estrogenic activity. Since we know the A:A ratio of these hormones from the vida, we consider those values too, hence our A:A:E ratio is a hybrid equivalence claim based off bioassay studies and A:A ratios mainly from the vida.
In essense, we wanted to give people a general ballpark of effects from andro products. In theory, deriving a testosterone equivalent value from estrogen is possible. This of course on the most extreme end of the spectrum. The effects of DHT and testosterone are closer than the effects of testosterone and estrogen IMO. (probably a 70% overlap between T and DHT, with maybe only 30-40% overlap between T and E)
The 375mg/week TE claim for AH makes sense in a real world setting. You would have a hard time differentiating a full dose of AH vs. 375mg/week of injectable T enanthate by examining end user results, bloods, physical examination, etc. The differences would become more clear as months went on, but would still be similar.
Eitherway, bioassays are being used now to calculate the appropriate dose of DHT for TRT by simply measuring the total "androgen" activity. Naturally, the science will evolve, and we will see total estrogen activity measured in the TRT seeking male too. There is more logic in calculating the sum of hormone activity, rather than individual hormones. Its just a matter of correlating total "sum" estrogen or androgen activities with blood levels of individual hormones, creating an economical bioassay test, and implementing this in a clinical setting. Id say in the next 10-15 years we will see docs testing for "androgen activity" rather than T levels. I
I expanded on this a bit last year on SHR - # 655 - New Methods Of HRT PLUS A1 And A2 Milk.. Do You Know What You Are Drinking? - Super Human Radio - The World's First Broadcast Radio Show Dedicated to Human Performance